Centanafadine

DB14841ApprovedInvestigationalSmall molecule

Centanafadine is a once-daily norepinephrine-dopamine-serotonin reuptake inhibitor and CNS stimulant indicated for ADHD in adults and pediatric patients. Centanafadine is a reuptake inhibitor at the norepinephrine, dopamine, and serotonin transporters and a central nervous system stimulant.

Mechanism: Pharmacologically active on Sodium-dependent noradrenaline transporter, Sodium-dependent dopamine transporter, and Sodium-dependent serotonin transporter
Curator reviewed
Primary indication: Centanafadine is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years of age and older weighing at least 20 kg.Curator reviewed · 1 structured indication
Formula / weight: C₁₅H₁₅N · 209.292 g/mol (avg)
Code names: EB-1020

Resolves to

Compound

UNIID2A6T4UH9CCAS924012-43-1ChEMBLCHEMBL3301621

Structure

InChIKeyHKHCSWPSUSWGLI-CABCVRRESA-NSMILESC1[C@@H]2CNC[C@]12C1=CC=C2C=CC=CC2=C1

Targets

P23975SLC6A2Q01959SLC6A3P31645SLC6A4

What you can answer from here — as of September 16, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

244Drug interactionsStructured to mechanism, not free text

17Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Centanafadine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account